Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 5/20 | 0.53 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 3/20 | 0.47 |
| ▸ | CCND1 | P24385 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22930065 | 0.98 | HTR2A (0.54) | HTR2AHTR2CHTR7PLGPLAU | |
| SCHEMBL15550237 | 0.98 | HTR2A (0.54) | HTR2AHTR2CHTR7PLGPLAU | |
| SCHEMBL28550149 | 0.98 | HTR2A (0.54) | HTR2AHTR2CHTR7PLGPLAU | |
| SCHEMBL4939152 | 0.95 | HTR2A (0.56) | HTR2AHTR2CHTR7PLGPLAU | |
| SCHEMBL14061899 | 0.88 | HTR2A (0.59) | HTR2AHTR2CHTR7PLGPLAU | |
| Dimethylamine SCHEMBL18941222 | 0.84 | HTR2A (0.55) | HTR2AHTR2CHTR7SLC6A2NTSR1 | |
| SCHEMBL28993624 | 0.84 | HTR2A (0.51) | HTR2AHTR2CHTR7PLGPLAU | |
| SCHEMBL30388499 | 0.84 | HTR2A (0.51) | HTR2AHTR2CHTR7PLGPLAU | |
| SCHEMBL15423256 | 0.83 | HTR2A (0.58) | HTR2AHTR2CHTR7PLGPLAU | |
| SCHEMBL18307589 | 0.83 | CDK4 (0.52) | HTR2AHTR2CPLGPLAUCDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10905769-B2 | Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2021-02-02 | — | — | US | disclosed |
| WO-2017082924-A1 | PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10905769-B2 | Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use | PLK1, POLR1E, POLK | HTR2A 4587/4885HTR2C 4526/4885HTR7 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.